Pharmaceuticals (Jun 2024)

Metformin Therapy for Acne Vulgaris: A Meta-Analysis

  • Lidia Szefler,
  • Weronika Szybiak-Skora,
  • Anna Sadowska-Przytocka,
  • Ryszard Zaba,
  • Barbara Wieckowska,
  • Katarzyna Lacka

DOI
https://doi.org/10.3390/ph17060728
Journal volume & issue
Vol. 17, no. 6
p. 728

Abstract

Read online

Acne vulgaris is a common disease, which occurs in adolescents as well as adults and has a significant influence on the patient’s quality of life (QoL) in every aspect. Due to resistance to standard therapies, it has become necessary to prospect for new treatment strategies. It is important to highlight that the diagnosis and treatment of the underlying cause of acne such as metabolic and hormonal disorders may significantly improve the effectiveness of acne treatment. The correlation between Insulin Resistance (IR) and acne has been proven. Both disorders share many common occurrence factors and activation pathways. Metformin, an antihyperglycemic agent, seems to be a possible therapy option, not only because of its insulin sensitizing ability but also via plenty of additional effects of this medicine. While the efficiency of metformin therapy in patients with acne and Polycystic Ovary Syndrome (PCOS) is well explored, it is still necessary to evaluate it in patients without any endocrinopathies. This meta-analysis aimed to estimate the effectiveness of oral metformin as a monotherapy in acne patients without PCOS or other endocrinopathies. Study selection was performed with included criteria such as no PCOS and other endocrinopathies diagnosed, oral administration of metformin, and metformin in monotherapy. Selected studies contained comparisons in the Global Acne Grading System (GAGS) before and after metformin therapy. Statistical analysis detected significant improvement in skin condition after treatment with metformin.

Keywords